Oksana Koneva

FDA review sought as Humacyte applies for approval of Acellular Tissue Engineered Vessel

FDA review sought as Humacyte applies for approval of Acellular Tissue Engineered Vessel
Humacyte files FDA application

Humacyte has submitted a supplemental Biologics License Application to the FDA for its Acellular Tissue Engineered Vessel, seeking approval as a new vascular access option for patients on hemodialysis.

The company described the filing as a significant milestone in its ongoing efforts to expand treatment options for individuals with kidney failure. Details on the timeline for FDA review or potential commercialization were not disclosed.

Humacyte previously presented interim Phase 3 V012 trial results for its Acellular Tissue Engineered Vessel in women receiving dialysis at Kidney Week, according to company disclosures. The firm has also released long-term clinical data showing the vessel demonstrated low susceptibility to atherosclerosis in 52 patients, as reported in prior results. These developments form part of Humacyte’s ongoing clinical evaluation of its vascular technology.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.